Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority to US201161470803P priority Critical Priority to US201161470624P priority Priority to US61/470,803 priority Priority to US61/470,624 priority Application filed by Genentech Inc filed Critical Genentech Inc Priority to PCT/US2012/031665 priority patent/WO2012135750A1/en Publication of NZ617249A publication Critical patent/NZ617249A/en Publication of NZ617249B2 publication Critical patent/NZ617249B2/en First worldwide family litigation filed litigation Critical (A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. ( en Inventor Klaus Hoeflich Mark Merchant Original Assignee Genentech Inc Priority date (The priority date is an assumption and is not a legal conclusion.
#Adding points in calcusyn pdf
Google Patents Combinations of akt inhibitor compounds and vemurafenib, and methods of useĭownload PDF Info Publication number NZ617249A NZ617249A NZ617249A NZ61724912A NZ617249A NZ 617249 A NZ617249 A NZ 617249A NZ 617249 A NZ617249 A NZ 617249A NZ 61724912 A NZ61724912 A NZ 61724912A NZ 617249 A NZ617249 A NZ 617249A Authority NZ New Zealand Prior art keywords cancer acceptable salt compound vemurafenib pharmaceutically acceptable Prior art date Application number NZ617249A Other versions NZ617249B2 In the present study we investigated the potential radiosensitizing effect of PCI-24781, a potent pan-histone deacetylase inhibitor (HDACi. Even with the use of modern treatment protocols, the prognosis remains reserved, with children with GBM having a mean survival of 1215 months. Google Patents NZ617249A - Combinations of akt inhibitor compounds and vemurafenib, and methods of use Glioblastoma (GBM) is considered to be one of the most aggressive tumors of the central nervous system (CNS).
NZ617249A - Combinations of akt inhibitor compounds and vemurafenib, and methods of use
0 kommentar(er)
